Background and Aims: Vedolizumab is an IgG1 anti-α4β7 integrin antibody approved for the treatment of inflammatory bowel diseases [IBD], but without clear safety data during conception, pregnancy and nursing. Animal studies showed that mucosal vascular addressin cell adhesion molecule 1 [MAdCAM-1] is expressed by maternal vessels in the placenta and recruits α4β7-expressing cells that are considered important for maternal/fetal tolerance. Blocking this interaction by vedolizumab might affect this process. We aimed to evaluate pregnancy outcomes in vedolizumab-treated female IBD patients. Methods: We conducted a retrospective, multicentre Belgian observational study. Details on disease activity, prenatal complications, delivery and neonatal outcome were collected through a case report form. Results: Twenty-four pregnancies were reported. Five women had active disease at conception and one patient flared during pregnancy. There were 23 live births. Complications were observed in 25% of pregnancies [premature rupture of membranes, pre-eclampsia, miscarriage, elective termination and stillbirth] and in 35% of infants [prematurity, intra-uterine growth retardation, small for gestational age and congenital malformations including hip dysplasia, pulmonary valve stenosis and Hirschprung's disease]. Vedolizumab was continued throughout pregnancy in two females and stopped in the 1st and 2nd trimester in five and 16 patients, respectively. For live born children, the median [interquartile range] gestational age, weight and Apgar score 5 min after birth were 39 [37-39.6] weeks, 3270 [3080-3585] grams and 10 [9-10], respectively. Conclusions: Although several complications were observed, both in mothers and in newborns, no firm conclusions can be drawn. Awaiting prospective and controlled registries, vigilance and strict follow-up of pregnant patients treated with vedolizumab seems mandatory.
Introduction
Inflammatory bowel diseases [IBD] are characterized by chronic intestinal inflammation with a relapsing and remitting course, mostly affecting men and women of childbearing age. 1 As active disease is associated with poor pregnancy outcome in women with IBD, it is crucial to achieve and maintain clinical remission prior to conception as well as throughout pregnancy. 2 Although a wide variety of biological therapies have shown efficacy in this situation, safety data are scarce. [2] [3] [4] Most evidence for the use of biologicals in pregnancy exists for anti-tumour necrosis factor [anti-TNF] antibodies. 5, 6 Anti-TNF agents are also the only biological agents included in the European guidelines on reproduction and pregnancy in IBD patients. 2 Of the anti-TNF therapies, certolizumab pegol is considered the safest biological during pregnancy, because it does not cross the placental barrier. 6 However, this pegylated anti-TNF agent is not available in most European countries.
Vedolizumab [VDZ] was approved by the European Medicines Agency [EMA] in 2014 for the treatment of moderate to severe Crohn's disease [CD] and ulcerative colitis [UC] patients. 7, 8 VDZ is an intravenous humanized IgG1 monoclonal antibody targeting the interaction between α4β7 integrin and mucosal vascular addressin cell adhesion molecule 1 in the gut. 9 As VDZ is considered to be gut-focused, it is generally presumed that it has an excellent safety profile. However, safety data on VDZ exposure during pregnancy are very limited. [10] [11] [12] Importantly, murine experiments have shown that MAdCAM-1 is expressed by maternal vessels during placental development and recruits α4β7-expressing cells of the macrophage/monocyte lineage, which are assumed to play a role in maternal/ fetal tolerance. 13 In humans, placental expression of MAdCAM-1 was confirmed, although it seems to be only expressed during the first trimester of pregnancy and is absent in the placenta at birth.
14 It stands to reason that blocking this α4β7 integrin-MAdCAM-1 interaction by VDZ might affect pregnancy and lead to maternal and/or fetal complications. The aim of this study was therefore to evaluate the outcome of pregnancies in female IBD patients treated with VDZ. 
Materials and methods

Patient population
Data collection
Data were retrospectively collected at all participating centres by review of medical records and delivery reports after ethical approval by the Ethics Committee of the University Hospitals Leuven, Leuven, Belgium [S60985]. In addition, the mothers were contacted to provide information about infections, vaccinations and hospitalizations of the children during the first year of life. Preconception data included patient characteristics at conception (IBD diagnosis and previous IBD-related medical history, obstetric history [number of previous pregnancies, miscarriages and elective terminations as well as possible complications and outcomes of previous pregnancies], comorbidity, C-reactive protein [CRP] level prior to conception, disease activity based on physician global assessment [PGA] and concomitant use of medication at conception). PGA options correspond to 'active disease', 'flare' or 'remission', and were based on the clinical judgement of the treating gastroenterologist.
Information collected during pregnancy consisted of the following: date of conception, smoking and drinking habits during pregnancy, use of folic acid supplementation, dose and duration of VDZ therapy, reason for VDZ discontinuation in pregnancy, other IBD medication during pregnancy (including topical therapy, mesalamine, systemic steroids, immunomodulators, anti-TNF therapy and ustekinumab [UST]), disease activity [PGA] , changes in treatment [dose escalation or de-escalation, change in time interval or initiation of other treatments] per trimester of pregnancy, and complications such as placenta praevia, [pre-]eclampsia, infections during pregnancy, intra-uterine growth retardation, fetal loss or elective termination and premature rupture of the membranes [PROM] . In addition, we collected data on mode and term of delivery and newborn characteristics and complications [gestational age, sex, birth weight, Apgar scores at 1 and 5 min, congenital malformations, intensive care unit admission, allergies, vaccinations, breastfeeding, severe infectious complications and malignancies occurring in the first year of life]. Regarding severe infections or malignancies we collected data on the date of diagnosis, type of infection or tumour, need for hospitalization and length of hospitalization, treatment and outcome. In case of missing data, general practitioners were contacted to retrieve the information.
Outcomes and definitions
The primary aim of this study was to assess pregnancy outcome in VDZ-treated female IBD patients. 18 congenital anomalies, admission to a neonatal intensive care unit, serious infection or malignancy during the first year of life or at last follow-up. The first trimester was characterized as the time from conception until week 13 of gestation, the second trimester from week 13 to 26 and the third trimester from week 26 until delivery. Severe infectious complications in the newborn were regarded as infectious complications requiring or prolonging hospitalization. IBD disease activity was retrospectively assessed at conception and during each trimester of pregnancy by using PGA.
Vedolizumab administration
Since March 2009, VDZ has been used for the treatment of IBD patients as part of multiple trials. 7, 8 In Belgium, classical induction with commercial VDZ for both UC and CD consists of an intravenous [IV] dose of 300 mg at weeks 0, 2 and 6 followed by an 8-weekly IV maintenance dose of 300 mg. Of note, most patients with CD receive an extra induction dose of 300 mg IV VDZ at week 10. Patients who lose response to VDZ throughout follow-up can be optimized to 300 mg IV every 4 weeks through a medical needs programme, provided that objective signs of disease relapse are present.
Statistical analysis
Descriptive statistics were used to display the results. For nominal data, proportions and percentages were reported whereas for [non-parametric] continuous data medians with interquartile ranges [IQRs] were presented. The IBM SPSS Statistics 25.0 software package was used (Armonk, New York, USA). A p-value < 0.05 was regarded as statistically significant.
Results
Study population
Eleven Belgian hospitals reported 24 pregnancies in 24 unique women with IBD treated with VDZ since March 2009. Four women [17%] were included in the GEMINI trials at the time of conception and had to discontinue the study agent as per protocol. However, after being excluded from the trial, two of those patients still received VDZ through a medical needs programme. All other women [n = 20, 83%] were treated with VDZ in routine clinical practice at the time of conception or during pregnancy. Three pregnancies did not lead to a live birth. The remaining 21 pregnancies led to 23 live births [61% female], which included two dizygotic pairs of twins.
Maternal baseline characteristics and medication use in pregnancy
Maternal characteristics are displayed in Table 1 . All but two women were on VDZ maintenance treatment at conception either every 8 [n = 17] or 4 weeks [n = 5], with one patient needing dose optimization in the second trimester to VDZ 300 mg every 4 weeks. The two exceptions include patients who received VDZ induction therapy at week 4 of pregnancy, due to either disease activity or loss of response to anti-TNF therapy, not knowing they were pregnant. Figure 1 shows the use of VDZ at conception and during pregnancy.
At conception, five women had clinically active disease. Disease activity persisted until the first trimester of pregnancy in two patients and until the second trimester in one patient. The remaining two patients had incessant disease activity throughout pregnancy. One patient, who was in remission at conception, flared during the third trimester of pregnancy. The latter patient started VDZ therapy in combination with prednisolone suppositories at gestational week 4 after loss of response to anti-TNF therapy. After induction, topical steroids could be stopped and VDZ was given at a dose of 300 mg IV every 8 weeks until gestational week 22 when the last infusion was given. During the third trimester of pregnancy, topical steroids were restarted because of a flare.
VDZ was stopped in the first or second trimester of pregnancy in five and 16 cases, respectively. Two patients continued VDZ infusions throughout pregnancy due to persistent disease activity, and one patient was still using VDZ when she miscarried at week 6. In 87% of patients [n = 20] VDZ was stopped after multidisciplinary consultation. In one case, VDZ was stopped at the request of the patient because of arthralgia, despite having active disease. Postpartum, 86% [18/21] of patients who had stopped VDZ in pregnancy restarted VDZ therapy. No allergic reaction after re-induction was identified. Concomitant medication during pregnancy is shown in Supplementary Figure 2 . Mesalamine, anti-TNF therapy and azathioprine were used as part of maintenance treatment, while steroids were initiated because of either active disease [n = 2] or erythema nodosum [n = 1].
Pregnancy outcomes and complications
Previous pregnancies were reported in 63% [15/24] of the women and these pregnancies were complicated in 47% [7/15] of cases. These included pregnancy and neonatal complications such as antenatal hydronephrosis, IBD flare during pregnancy, PROM, preterm delivery and a history of multiple miscarriages. Only one of these patients now had an uncomplicated pregnancy.
Of the current pregnancies, as mentioned above, three did not lead to a live birth including an early miscarriage at 6 weeks of gestation in a patient with a history of idiopathic miscarriages. Underlying active disease, although not obvious clinically, may be an explanation for the miscarriages. The second case was an active termination at week 9 of gestation due to relational problems and thus independent of underlying IBD. The last one was a stillbirth at 22 weeks of gestation because of chorioamnionitis in a patient with a history of a late preterm delivery at 36 weeks. After fetal loss, this patient was switched to UST because of persistent disease activity. Since switching her therapy, she has become pregnant twice with the first pregnancy ending in a miscarriage at week 4. The second pregnancy was complicated by cervical insufficiency. She had to be hospitalized from weeks 23 to 32 due to risk of extreme premature delivery and eventually delivered at week 37. Other pregnancy complications included pre-eclampsia [n = 1] and PROM [n = 2].
Infants' baseline characteristics and neonatal complications
In the 23 children who were born alive, the median gestational age, Apgar score at minute 5 and birth weight were respectively 39 weeks Medication to which these children were exposed in utero is displayed in Table 2 . Furthermore, four infants were born late premature [weeks 34-36.5] and one child, part of a twin, was small for gestational age [2390 g at week 37]. This twin also experienced intra-uterine growth retardation. The proportion of neonatal complications to adverse pregnancy outcomes is displayed in Supplementary Figure 3 
Discussion
This study reports on the outcome of 24 pregnancies in VDZ-treated female IBD patients, which resulted in 23 live births including two dizygotic twins. In our cohort, 25% of the pregnancies were complicated and 35% of the infants experienced problems, including three children with congenital anomalies. To our knowledge, this is the largest cohort study reporting on pregnancy outcomes in female patients treated with VDZ. IBD typically affects women at a childbearing age 20 and previous studies have shown that disease activity at any time in pregnancy, rather than medication used to treat IBD, is the most important risk factor for unfavourable pregnancy outcome. 2, 16 In accordance with the Food and Drug Administration [FDA], VDZ can be used in pregnancy, despite the fact that studies on fetotoxicity in humans are lacking and no long-term data are available. 21 Furthermore, IBD is associated with adverse events in pregnancy such as preterm delivery, low birth weight, small for gestational age, preeclampsia, miscarriages and elective terminations. 22, 23 In addition, one study showed that children born to women with UC had a higher risk for congenital malformations. 23 However, so far no other study was able to confirm this. 24 Although our retrospective study did not include a control group, we observed complications with frequencies in the same range as those reported in previous historical case series with other biological agents. [25] [26] [27] Most of these complications, such as preterm delivery, small for gestational age, miscarriage and stillbirth, can be explained by underlying active IBD disease. In our relatively small cohort, the major confounding factor for poor pregnancy outcome seems to be the presence of active disease at conception and during pregnancy. Although the number of patients with active disease reported in our study was low, this was based on PGA and not on objective measures of disease activity. In addition, 45% of women did have an elevated CRP before conception, which also suggests the presence of active disease, making these women more at risk of pregnancy complications. In addition, the child that was small for gestational age was part of a twin and these pregnancies are themselves considered as being high-risk. Regarding the congenital anomalies described here [hip dysplasia, congenital pulmonary valve stenosis and Hirschsprung's disease], no association was found between the mechanism of action of VDZ and the underlying molecular pathways of these malformations. However, based on our study a possible causal relationship between VDZ and the mentioned complications cannot be excluded or confirmed due to the low number of patients and the presence of other underlying risk factors [mainly active disease] that may have contributed to these complications. The same probably goes for other anomalies that have been reported in the literature such as agenesis of the corpus callosum in a child of a healthy volunteer exposed to VDZ. 12 In addition, the pregnancy complications mentioned in our cohort [PROM, pre-eclampsia, elective termination and spontaneous miscarriage] are also seen with IBD patients not treated with biologicals or treated with biological agents other than VDZ. Thus, these complications are presumably also connected to the disease itself rather than the medication that was used.
The collaborating hospitals used VDZ in pregnancy in a similar way as anti-TNF therapy because they are both IgG1 monoclonal antibodies. So, when feasible and as is customary in Europe, VDZ therapy was stopped during the second trimester of pregnancy. However, applying identical rules to VDZ and anti-TNF therapy in pregnancy may not be appropriate because VDZ has a longer half-life than anti-TNF agents. Therefore, discontinuation of VDZ in the 2nd trimester may lead to significantly higher serum levels in the infant compared to infliximab, 9,11 which theoretically may have implications for the administration of live-attenuated vaccines as well as the newborn's risk of infections. Currently, European and American guidelines do not recommend the administration of live-attenuated vaccines during the first 6 months of life in children exposed to biologicals in utero. 2, 28, 29 In Belgium, this only concerns Rotavirus vaccination. 19 However, these guidelines are based solely on treatment with anti-TNF therapy because data regarding live-attenuated vaccination in VDZ-exposed children are absent. Why 45% of the infants in our population received Rotavirus vaccination despite active discouragement remains unknown. Nevertheless, no adverse events were documented after vaccination. Meanwhile, response to non-live vaccines was shown to be normal in children exposed to biologicals in utero. 30, 31 However, this should be interpreted with caution as only one child was exposed to VDZ. Another concern is the possible effect of biologicals on the development of the infant's immune system and infection risk. First, trials with anti-TNF therapy reported conflicting results. Preliminary data from the PIANO registry showed a higher risk of infection in newborns exposed to a combination of anti-TNF therapy and immunomodulator. 27 By contrast, the recently published TEDDY study demonstrated reassuring results in a similar population of children. 28 Furthermore, studies on the effect of anti-TNF exposure in utero on the development of the infant's immune system also resulted in inconsistent results. 29, 32 However, there is no evidence available on the effect of VDZ on the immune system and infection risk of the newborn, so no recommendations can be made. In our study, only one child was hospitalized for an infection during the first year of life, although this should be interpreted with caution due to the short follow-up time postpartum.
Regarding lactation in females treated with VDZ, only three studies have been published so far: one in monkeys receiving a supratherapeutic dose of VDZ 11 and two in humans. 33, 34 The studies demonstrated the presence of VDZ in breast milk, yet in very small doses. In addition, it is presumed that these small amounts of VDZ will be degraded in the infant's gastrointestinal tract and thus will not substantially impact the immune system. 33 In spite of current guidelines, only 52% of children in our population were breastfed. No explanation for this could be found, but despite recommendations of breastfeeding, mothers may still have concerns about neonatal exposure to medication through breast milk.
Hence, the main emphasis should still be on preconception consultation in which concerns with respect to medication use, breastfeeding and vaccination should be addressed. Furthermore, the importance of good disease control should be stressed and the physician should ensure that the patient understands the value of disease control prior to conception as well as during pregnancy.
Our study has some limitations with the main one being the low number of cases and the fact that no control group was used, because this prevents us from drawing firm conclusions regarding the use of VDZ in pregnancy. For this, we need to await the results of large ongoing prospective registries in the years to come. Although our cohort reflects real world data, it contains a very heterogeneous group of patients due to the diverse use of concomitant medication, the different setting of VDZ initiation [placebo-controlled trial vs daily clinical practice] and the onset of VDZ initiation [months after conception, just before or just after conception]. Second, although we requested reports of all pregnancies under VDZ, the retrospective nature of this study makes it prone to selection bias in which either patients with unfavourable pregnancy outcomes might be over-reported or early miscarriages might have been missed. Indeed, patients may not always inform their treating gastroenterologists of their pregnancy. Finally, disease activity was retrospectively assessed using the PGA, which is known to correlate poorly with endoscopic and biological disease activity, as reflected in the fact that only five women were assessed as having clinically active disease, although biologically 45% had an elevated CRP. Missing of other objective markers of disease activity such as endoscopic evaluation or faecal calprotectin is therefore also a limitation, and underlying active disease remains a major confounding factor in our cohort.
Conclusion
This is the largest cohort study reporting on pregnancy outcomes in patients treated with VDZ. Although the number of pregnancies remains low and no guidelines are available, our results support the fact that VDZ should only be used in pregnancy if the benefits for the mother outweigh the potential risks for the mother and [unborn] child. In the future, results from ongoing registries will hopefully shed more light on the safety of VDZ in pregnancy and lactation. Furthermore, large prospective studies are needed, not only on pregnancy outcomes with VDZ, but also regarding VDZ trough levels in the mother and newborn. In addition, the function of the α4β7-MAdCAM1 interaction in the placenta should be further explored. In the meanwhile, vigilance and strict follow-up of pregnant patients with IBD treated with VDZ are warranted.
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